Theravance Biopharma Inc., of Dublin, said it intends to offer 4.25 million shares in a public offering and plans to grant underwriters a 30-day option to purchase up to 637,500 additional shares. Share price has not yet been disclosed. Leerink Partners and Evercore ISI are acting as the joint book-running managers. Proceeds are expected to support general corporate purposes, which may include research activities, preclinical and clinical development, manufacture of preclinical, clinical and commercial-drug supplies, working capital and acquisitions of technology or drug candidates. Shares of Theravance (NASDAQ:TBPH) closed Thursday at $21.16, down $2.41, or 10.2 percent.